MedPath

Allogeneic hematopoietic stem cell transplantation from a two HLA-haplotype-mismatched family donor for post-transplant relapse/rejection: A prospective phase II study with statistical validation for survival benefit

Phase 2
Conditions
hematologic malignancies relapsing or with rejection after allogeneic hematopoietic stem cell transplantation
Registration Number
JPRN-UMIN000043973
Lead Sponsor
Hyogo College of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

1) serum Cre >2.0 mg/dl 2) serum T-Bil >2.0 mg/dl 3) selum AST and/or ALT >200 U/L 4) EF <45% 5) SpO2 <95% (room air) 6) PS (ECOG score) 3-4

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath